摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Amino-2-benzylthio-5-cyan-pyrimidin | 100137-41-5

中文名称
——
中文别名
——
英文名称
4-Amino-2-benzylthio-5-cyan-pyrimidin
英文别名
4-amino-2-benzylsulfanyl-pyrimidine-5-carbonitrile;4-amino-2-benzylmercapto-pyrimidine-5-carbonitrile;4-Amino-2-benzylmercapto-pyrimidin-5-carbonitril;4-Amino-2-benzylsulfanylpyrimidine-5-carbonitrile
4-Amino-2-benzylthio-5-cyan-pyrimidin化学式
CAS
100137-41-5
化学式
C12H10N4S
mdl
——
分子量
242.304
InChiKey
OKQFKUDLHVFDOE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    101
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    4-Amino-2-benzylthio-5-cyan-pyrimidin间氯过氧苯甲酸 作用下, 以 二氯甲烷 为溶剂, 以95%的产率得到
    参考文献:
    名称:
    Novel Hepatitis C virus replicon inhibitors: Synthesis and structure–activity relationships of fused pyrimidine derivatives
    摘要:
    The synthesis of several pyrido[2,3-d] pyrimidine and pyrimido[4,5-d] pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.01.096
  • 作为产物:
    参考文献:
    名称:
    Novel Hepatitis C virus replicon inhibitors: Synthesis and structure–activity relationships of fused pyrimidine derivatives
    摘要:
    The synthesis of several pyrido[2,3-d] pyrimidine and pyrimido[4,5-d] pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.01.096
点击查看最新优质反应信息

文献信息

  • ANTI-VIRAL COMPOUNDS
    申请人:Betebenner A. David
    公开号:US20070197558A1
    公开(公告)日:2007-08-23
    Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    本发明公开了一种有效抑制丙型肝炎病毒(“HCV”)或其他病毒复制的化合物。本发明还涉及包含这些化合物的组合物、这些化合物与其他抗病毒或治疗剂的联合配方或联合给药、合成这些化合物的过程和中间体,以及使用这些化合物治疗HCV或其他病毒感染的方法。
  • Anti-viral compounds
    申请人:Abbott Laboratories
    公开号:US07915411B2
    公开(公告)日:2011-03-29
    Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    本发明揭示了一种有效抑制丙型肝炎病毒(“HCV”)或其他病毒复制的化合物。本发明还涉及包含这些化合物的组合物、这些化合物与其他抗病毒或治疗剂的共同配方或共同管理、合成这些化合物的过程和中间体,以及使用这些化合物治疗HCV或其他病毒感染的方法。
  • Antiviral compounds
    申请人:Abbott Laboratories
    公开号:EP2345652A1
    公开(公告)日:2011-07-20
    The present invention is directed to the use of compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses, tautomers of said compounds, or pharmaceutically acceptable salts of said compounds or tautomers, for the manufacture of a medicament for the treatment of HCV.
    本发明涉及使用能有效抑制丙型肝炎病毒("HCV")或其他病毒复制的化合物、所述化合物的同系物或所述化合物或同系物的药学上可接受的盐,制造治疗 HCV 的药物。
  • US2698326
    申请人:——
    公开号:——
    公开(公告)日:——
  • US7915411B2
    申请人:——
    公开号:US7915411B2
    公开(公告)日:2011-03-29
查看更多